Ipca Laboratories is expecting to maintain 24% margins in FY15. The company’s domestic business in Q4 has grown 16% and the formulation export business has been up 19% on a year-on-year basis.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
